World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation
复制标题
DOI：
10.3109/15622975.2015.1009163
复制
发表时间：
2015-04-01
影响因子：
3.1
通讯作者：
Moeller, Hans-Juergen
中科院分区：
文献类型：
--
作者：
Hasan, Alkomiet;Falkai, Peter;Moeller, Hans-Juergen
这些更新的指南以2005年和2006年出版的世界生物精神病学学会联合会（WFSBP）精神分裂症生物治疗指南第一版为基础。对于2015年的修订，系统地审查了所有与精神分裂症生物治疗有关的现有出版物，以便进行循证更新。这些指南提供了临床和科学相关的循证实践建议。它们旨在供所有诊断和治疗精神分裂症患者的医生使用。在这些指南第一版的基础上，对这次更新进行了系统审查，并从国家指南中提取了数据。对已确定的文献根据其有效性的证据强度进行评估，随后将其分为六个证据级别（A-F）和五个推荐级别（1-5）。更新指南的第三部分涵盖了以下具体治疗情况的管理：共病抑郁症、自杀、各种共病物质使用障碍（合法和非法药物）以及妊娠和哺乳期。这些指南主要关注精神分裂症患者的生物治疗（包括抗精神病药物和其他药物治疗方案）。
These updated guidelines are based on the first edition of the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia published in the years 2005 and 2006. For this 2015 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations which are clinically and scientifically relevant. They are intended to be used by all physicians diagnosing and treating patients with schizophrenia. Based on the first version of these guidelines a systematic review, as well as a data extraction from national guidelines have been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and subsequently categorised into six levels of evidence (A-F) and five levels of recommendation (1-5). This third part of the updated guidelines covers the management of the following specific treatment circumstances: comorbid depression, suicidality, various comorbid substance use disorders (legal and illegal drugs), and pregnancy and lactation. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication and other pharmacological treatment options) of patients with schizophrenia.